Following the completion of the proposed merger between Oxford GlycoSciences (OGS) and Cambridge Antibody Technology (CAT), both based in the UK, CAT will continue to be chaired by Peter Garland. Peter Chambré will remain CEO and John Aston CFO of the merged company.
David Ebsworth, CEO of OGS, will be invited to join CAT’s board as an executive director to assist in the integration process. After that, he intends to remain on the CAT board as a non-executive director. David Glover will remain as Chief medical offier CAT. Raj Parekh, CSO of OGS, will be invited to join the CAT board as an executive director upon completion of the merger. Following a “portfolio review” of the combined company, he intends to remain on the CAT board as a non-executive director. Chris Moyses, currently chief medical offier of OGS, and Denis Mulhall, currently CFO of OGS, will be invited to join the CAT executive committee.
James Hill, currently a non-executive director of OGS, will be invited to join the CAT board as a non-executive director.
Steve Holmes has become senior director for therapeutic targets at antibody drug discovery company Domantis, based in Cambridge, UK. He joins the company from Oxford GlycoSciences, where he was director of antibody discovery. Prior to that, he was head of high-throughput biology for Europe at GlaxoSmithKline and held various senior scientific management posts at SmithKline Beecham before that. Holmes holds a BSc in organic chemistry and physiology and a PhD in thyroid autoimmune disease from the University of Sheffield.